Show simple item record

dc.contributor.authorKristeleit, R.
dc.contributor.authorClamp, Andrew R
dc.contributor.authorGourley, C.
dc.contributor.authorRoux, R.
dc.contributor.authorHall, M.
dc.contributor.authorDevlin, M. J.
dc.contributor.authorNirsimloo, R.
dc.contributor.authorKounnis, V.
dc.contributor.authorHughes, L.
dc.contributor.authorCounsell, N.
dc.contributor.authorFarrelly, L.
dc.contributor.authorMiller, R.
dc.date.accessioned2023-01-24T10:32:22Z
dc.date.available2023-01-24T10:32:22Z
dc.date.issued2022en
dc.identifier.citationKristeleit R, Clamp AR, Gourley C, Roux R, Hall M, Devlin MJ, et al. Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial. Annals of Oncology. 2022 Sep;33(7):S783-S. PubMed PMID: WOS:000866211600514.en
dc.identifier.doi10.1016/annonc/annonc1054en
dc.identifier.urihttp://hdl.handle.net/10541/625959
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/annonc/annonc1054en
dc.titleEfficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment Of Oncology, Guy's and St Thomas' NHS Foundation Trust, SE1 9RTen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record